# Colchicine for Primary Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes

Study · id `cardio:ct-nct07837934` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07837934](<https://clinicaltrials.gov/study/NCT07837934>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07837934

Browse, organ or system: Blood vessels; Metabolism  
Browse, condition area: Coronary and vascular disease; Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 300 participants.

## Technical summary

Registry record NCT07837934. Randomized; quadruple masking; primary purpose prevention. Start 2025-07-24 (actual); primary completion 2027-07-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase: Phase 2
- Enrolled: 300 participants (planned count; ClinicalTrials.gov record NCT07837934, source copy `cardio:ctgov-nct07837934-2026-09-24`, retrieved 2026-10-26)
- Started: 2025-07-24 (actual) (ClinicalTrials.gov record NCT07837934, source copy `cardio:ctgov-nct07837934-2026-09-24`, retrieved 2026-10-26)
- Primary completion: 2027-07-31 (anticipated) (ClinicalTrials.gov record NCT07837934, source copy `cardio:ctgov-nct07837934-2026-09-24`, retrieved 2026-10-26)
- Completion: 2027-07-31 (anticipated) (ClinicalTrials.gov record NCT07837934, source copy `cardio:ctgov-nct07837934-2026-09-24`, retrieved 2026-10-26)
- Countries: Singapore (ClinicalTrials.gov record NCT07837934, source copy `cardio:ctgov-nct07837934-2026-09-24`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07837934-2026-09-24`, retrieved 2026-10-26)

## The registry's words

- Brief title: Colchicine for Primary Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes
- Acronym: Col-DM
- Condition: Type 2 Diabetes Mellitus (T2DM)
- Condition: Atherosclerosis
- Condition: Cardiovascular Diseases
- Intervention (Drug): Colchicine 0.5 MG Oral Tablet Once Daily
- Intervention (Drug): Placebo
- Lead sponsor: Tan Tock Seng Hospital
- Lead sponsor class: OTHER
- Collaborator: Nanyang Technological University
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Atherosclerosis (`cardio:atherosclerosis`)
- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry intervention name matches this record once doses, forms and salt words are removed: Colchicine (`cardio:colchicine`)
- Registry lists this organization as the lead sponsor: Tan Tock Seng Hospital (`cardio:org-tan-tock-seng-hospital`)

## Provenance

Content hash: ad88098a9048164fc43211aa59179c1098454d01f6145792e322d12870cf746f
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
